Skip To Main Content
Lilly
Menu closed
Lilly
  • Account Login / Register
  • Medical Home
  • Medical Education
      • All Therapeutic Areas
        • Alopecia Areata
        • Atopic Dermatitis
        • Psoriasis
        • Diabetes
        • Hypoglycemia
        • Inflammatory Bowel Disease
        • Ulcerative Colitis
        • COVID-19
        • Headache Disorders
        • Neurodegeneration
        • Breast Cancer
        • Hematologic Cancer
        • Axial Spondyloarthritis
        • Psoriatic Arthritis
        • Rheumatoid Arthritis
        • Resources
      • All Therapeutic Areas
        • Alopecia Areata
        • Atopic Dermatitis
        • Psoriasis
        • Diabetes
        • Hypoglycemia
        • Inflammatory Bowel Disease
        • Depression
        • Headache Disorders
        • Breast Cancer
        • Gastrointestinal Cancer
        • Oncology General
        • Osteoporosis
        • Rheumatoid Arthritis
        • Resources
  • Independent Medical Education
      • Alopecia Areata
      • Atopic Dermatitis
      • Psoriasis
    • Diabetes
      • Ulcerative Colitis
      • COVID-19
      • Headache Disorders
      • Neurodegeneration
    • Obesity
      • Breast Cancer
      • Gastrointestinal Cancer
      • Hematologic Cancer
      • Non-small Cell Lung Cancer
      • Prostate Cancer
      • Oncology General
      • Precision Medicine and Diagnostics
      • Axial Spondyloarthritis
      • Systemic Lupus Erythematosus
      • Psoriatic Arthritis
      • Rheumatoid Arthritis
  • Chat Contact Us

Clinicopathologic features of early vs late recurrence of HR+,HER2- EBC

Dr. O’Shaughnessy elaborates on the spectrum of high-risk HER+,HER2- early breast cancer and discusses the clinicopathologic features associated with early and late recurrence.

Date of Last Review: Feburary 14, 2023

Document Number: VV-MED-135247

Skip To Playlist
Clinicopathologic features of early vs late recurrence of HR+,HER2- EBC is now playing
1:28

Related Resources

Download PDF Medical Answer PDF Document Created with Sketch. INFOGRAPHIC: High-risk HR+,HER2- EBC Prognosis and Risk of Recurrence

As health care providers, it is important to recognize features associated with a higher risk of recurrence in HR+/HER2- early breast cancer. Learn more by viewing this infographic.

Are you satisfied with this content?
  • Copyright
  • Terms of Use
  • Privacy Statement
  • Accessibility Statement
  • Sitemap

To speak to customer support:
Call (XXX) XXX-XXXX

This site is intended for US Healthcare Professionals only.

4.2.0 05/2023 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2023. All rights reserved.

Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

Facebook Twitter
Lilly